Osiris Therapeutics Inc., of Columbia, Md., said data were presented at the 2010 BMT Tandem Meeting from a 59-patient study of stem cell product Prochymal in treatment-resistant pediatric graft vs

The 46-patient study involved women following laparoscopic-assisted hysterectomy

Data from the uncontrolled, dose-finding, 20-patient study showed half of the patients gained at least three lines of vision by 30 weeks

The head-to-head study also demonstrated efficacy of Stelara among patients in the study who failed to respond to Enbrel

The randomized, double-blind, placebo-controlled, 770-patient study will compare stroke outcome in patients treated with DP-b99 or placebo within a nine-hour therapeutic window

Chelsea Therapeutics International Ltd., of Charlotte, N.C., said the FDA agreed to allow the company to modify the primary endpoint and enroll an additional 24 patients in Study 301, its pivotal Phase III trial of Droxidopa in symptomatic neurogenic orthostatic hypotension

The 128-patient study will focus on finding the lowest dose that provides clinical benefit while minimizing adverse effects

Data from the 189-patient study also demonstrated opioid sparing through multiple secondary endpoints, including the percentage of patients who were opioid free in the Exparel group vs

Preliminary evaluation of the 25-patient study found the response rate to be twice that expected from a risk-matched historical, consistent with findings from an earlier Phase Ib trial

In separate news, the company said data from an 18-patient study of NGX426, an oral, nonopioid AMPA/kainite receptor antagonist, showed that the 150-mg dose demonstrated statistically significant reductions in spontaneous pain vs

Patients in the study had been diagnosed with high-grade vulvar intraepithelial neoplasia

Data from the 315-patient study are expected in the second quarter of 2010

Data from the 12-patient study were presented at the North American Cystic Fibrosis meeting in Minneapolis

Data from the 51-patient study were presented at the Retina Congress 2009 meeting in New York

Among the data presented included results from a Phase II, 73-patient study in venous stasis ulcers showing that the all doses of Tß4 were well tolerated, with the mid-dose group showing a 33.3 percent response rate in time to healing compared to 23.5 percent in the placebo group, and Tß4 decreased the median time to healing by 45 percent among all groups

Chelsea Therapeutics International Ltd., of Charlotte, N.C., reached its target enrollment of 118 randomized patients for Study 301, the second of two pivotal Phase III trials in Chelsea's registration program of Droxidopa for the treatment of symptomatic, neurogenic orthostatic hypotension...The 151-patient study in patients with acute moderate to severe muscle spasms in the lumbar region was conducted at 17 sites in the U.S

But data from the 263-patient study did suggest that treatment with tafoxiparin provided beneficial effects, including a statistically significant reduction in the number of women with labor times in excess of 12 hours, as well as fewer complications as a cause of protracted labor and fewer Caesarean sections

The 24-patient study is designed to compare the effectiveness and safety of two low doses of NeoFuse with autograft...The eight-week, 100-patient study is expected to assess the drug's safety as the primary endpoint, with a secondary objective of estimating the beneficial effect of NT-11624 on the reduction of pain compared to placebo

In the randomized, double-blind, placebo-controlled, 259-patient study, pain intensity scores were 78.2 12.4 for Ereska and 47.9 12.3 for placebo (p = 0.053